Literature DB >> 8698454

Bacterially induced bone destruction: mechanisms and misconceptions.

S P Nair1, S Meghji, M Wilson, K Reddi, P White, B Henderson.   

Abstract

Normal bone remodelling requires the coordinated regulation of the genesis and activity of osteoblast and osteoclast lineages. Any interference with these integrated cellular systems can result in dysregulation of remodelling with the consequent loss of bone matrix. Bacteria are important causes of bone pathology in common conditions such as periodontitis, dental cysts, bacterial arthritis, and osteomyelitis. It is now established that many of the bacteria implicated in bone diseases contain or produce molecules with potent effects on bone cells. Some of these molecules, such as components of the gram-positive cell walls (lipoteichoic acids), are weak stimulators of bone resorption in vitro, while others (PMT, cpn60) are as active as the most active mammalian osteolytic factors such as cytokines like IL-1 and TNF. The complexity of the integration of bone cell lineage development means that there are still question marks over the mechanism of action of many well-known bone-modulatory molecules such as parathyroid hormone. The key questions which must be asked of the now-recognized bacterial bone-modulatory molecules are as follows: (i) what cell population do they bind to, (ii) what is the nature of the receptor and postreceptor events, and (iii) is their action direct or dependent on the induction of secondary extracellular bone-modulating factors such as cytokines, eicosanoids, etc. In the case of LPS, this ubiquitous gram-negative polymer probably binds to osteoblasts or other cells in bone through the CD14 receptor and stimulates them to release cytokines and eicosanoids which then induce the recruitment and activation of osteoclasts. This explains the inhibitor effects of nonsteroidal and anticytokine agents on LPS-induced bone resorption. However, other bacterial factors such as the potent toxin PMT may act by blocking the normal maturation pathway of the osteoblast lineage, thus inducing dysregulation in the tightly regulated process of resorption and replacement of bone matrix. At the present time, it is not possible to define a general mechanism by which bacteria promote loss of bone matrix. Many bacteria are capable of stimulating bone matrix loss, and the information available would suggest that each organism possesses different factors which interact with bone in different ways. With the rapid increase in antibiotic resistance, particularly with Staphylococcus aureus and M. tuberculosis, organisms responsible for much bone pathology in developed countries only two generations ago, we would urge that much greater attention should be focused on the problem of bacterially induced bone remodelling in order to define pathogenetic mechanisms which could be therapeutic targets for the development of new treatment modalities.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698454      PMCID: PMC174085          DOI: 10.1128/iai.64.7.2371-2380.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  106 in total

1.  Pathology of experimental Bordetella bronchiseptica infection in swine: atrophic rhinitis.

Authors:  J R Duncan; R F Ross; W P Switzer; F K Ramsey
Journal:  Am J Vet Res       Date:  1966-03       Impact factor: 1.156

2.  Turbinate osteoporosis in pigs following intranasal inoculation of purified Pasteurella toxin: histomorphometric and ultrastructural studies.

Authors:  M A Dominick; R B Rimler
Journal:  Vet Pathol       Date:  1988-01       Impact factor: 2.221

3.  Interactions between bacterial endotoxin and other stimulators of bone resorption in organ culture.

Authors:  L G Raisz; K Nuki; C B Alander; R G Craig
Journal:  J Periodontal Res       Date:  1981-01       Impact factor: 4.419

4.  Bacteroides (Porphyromonas) gingivalis fimbriae activate mouse peritoneal macrophages and induce gene expression and production of interleukin-1.

Authors:  S Hanazawa; Y Murakami; K Hirose; S Amano; Y Ohmori; H Higuchi; S Kitano
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

5.  Stimulation of bone resorption by inflamed nasal mucosa, dermonecrotic toxin-containing conditioned medium from Pasteurella multocida, and purified dermonecrotic toxin from P. multocida.

Authors:  T G Kimman; C W Löwik; L J van de Wee-Pals; C W Thesingh; P Defize; E M Kamp; O L Bijvoet
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

6.  Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle.

Authors:  B J Shenker; S Datar
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

7.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.

Authors:  G Girasole; R L Jilka; G Passeri; S Boswell; G Boder; D C Williams; S C Manolagas
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

8.  Mouse interleukin-1 receptor antagonist induced by Actinobacillus actinomycetemcomitans lipopolysaccharide blocks the effects of interleukin-1 on bone resorption and osteoclast-like cell formation.

Authors:  T Nishihara; Y Ohsaki; N Ueda; N Saito; G R Mundy
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  The effect of lipopolysaccharide from the oral bacterium Bacteroides gingivalis on osteoclastic resorption of sperm-whale dentine slices in vitro.

Authors:  H J Sismey-Durrant; R M Hopps
Journal:  Arch Oral Biol       Date:  1987       Impact factor: 2.633

10.  Parathyroid hormone and lipopolysaccharide induce murine osteoblast-like cells to secrete a cytokine indistinguishable from granulocyte-macrophage colony-stimulating factor.

Authors:  M C Horowitz; D L Coleman; P M Flood; T S Kupper; R L Jilka
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

View more
  122 in total

Review 1.  Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?

Authors:  J Ciampolini; K G Harding
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

2.  Osteomyelitis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

3.  Mycobacterium tuberculosis chaperonin 10 heptamers self-associate through their biologically active loops.

Authors:  Michael M Roberts; Alun R Coker; Gianluca Fossati; Paolo Mascagni; Anthony R M Coates; Steve P Wood
Journal:  J Bacteriol       Date:  2003-07       Impact factor: 3.490

4.  Assessment of lipopolysaccharide microleakage at conical implant-abutment connections.

Authors:  Sönke Harder; Elgar Susanne Quabius; Lars Ossenkop; Matthias Kern
Journal:  Clin Oral Investig       Date:  2011-12-02       Impact factor: 3.573

Review 5.  Osteoblast responses to bacterial pathogens: a previously unappreciated role for bone-forming cells in host defense and disease progression.

Authors:  Ian Marriott
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 6.  Endodontic-periodontal locally delivered antibiotics.

Authors:  Amela Lacević; Edina Vranić; Irfan Zulić
Journal:  Bosn J Basic Med Sci       Date:  2004-02       Impact factor: 3.363

7.  The significance of osteitis in rhinosinusitis.

Authors:  Neeraj Sethi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-04-27       Impact factor: 2.503

8.  Bone resorption caused by three periodontal pathogens in vivo in mice is mediated in part by prostaglandin.

Authors:  Y Zubery; C R Dunstan; B M Story; L Kesavalu; J L Ebersole; S C Holt; B F Boyce
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

9.  Whole Body Vibration Reduces Inflammatory Bone Loss in a Lipopolysaccharide Murine Model.

Authors:  I S Kim; B Lee; S J Yoo; S J Hwang
Journal:  J Dent Res       Date:  2014-05-08       Impact factor: 6.116

10.  Long Bone Osteomyelitis.

Authors:  Luca Lazzarini; Fausto De Lalla; Jon T. Mader
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.